DEF: CytoDyn Seeks Shareholder Approval for Capital Raise, Board Elections

CytoDyn Inc. announces its 2025 Annual Meeting of Stockholders to vote on director elections, auditor ratification, executive compensation, and a significant increase in authorized common stock.

Summary

• The 2025 Annual Meeting of Stockholders will be held virtually on November 21, 2025, at 9:30 a.m. Pacific Time.
• The record date for stockholders entitled to vote at the Annual Meeting is September 25, 2025.
• Key proposals include the election of five directors, advisory ratification of CBIZ CPAs P.C. as the independent auditor for fiscal year ending May 31, 2026, and advisory votes on named executive officer compensation and its frequency (Board recommends one year).
• A proposal to amend the Company's Certificate of Incorporation to increase the total number of authorized shares of common stock from 1,750,000,000 to 2,250,000,000 shares will be voted upon.
• A proposal for the adjournment of the Annual Meeting to solicit additional proxies is included, specifically if there are insufficient votes to approve the share increase proposal.
• As of September 25, 2025, the Company had 1,259,752,684 shares of common stock issued and outstanding.
• Approximately 307,000,000 shares are reserved for issuance upon the exercise of outstanding convertible notes, convertible preferred shares, warrants, performance share units, and stock options, with an additional 18,000,000 shares reserved under the 2012 stock incentive plan.
• Less than 10% of the currently authorized 1,750,000,000 shares of common stock remain available and unreserved for issuance.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the Company is addressing corporate governance and seeking necessary capital for future operations, the persistent 'going concern' doubt from auditors and the dismissal of an auditor due to SEC action are significant negative indicators. The proposed substantial increase in authorized shares, primarily for future financings, implies significant impending dilution for existing shareholders, which is a negative for current investors.

Positives

• All current directors are independent, and the Board leadership structure separates the Chair and Principal Executive Officer positions, with Tanya D. Urbach serving as non-employee independent Board Chair since January 2022.
• Established processes for assessing, identifying, and managing cybersecurity risks are in place, including external consultants, regular system tests, incident simulations, and employee training programs.
• A Code of Ethics and Business Conduct, Statement of Insider Trading Policy, and Anti-Hedging Policy have been adopted, applying to all directors, officers, and employees.
• The Audit Committee members are financially sophisticated, and Mr. Ryan M. Dunlap is designated as an audit committee financial expert.
• The Compensation Committee utilizes an independent compensation consultant (Aon/Radford) to benchmark executive and director compensation against a peer group of pre-commercial biotechnology companies.
• The executive compensation program is designed to align with stockholder interests, primarily through long-term equity incentives like stock options, which encourage focus on long-term stock price appreciation.
• An employee savings plan (401(k) Plan) is in place, with the Company making safe harbor qualified non-elective contributions equal to 3% of each participant's salary, which vest immediately.

Negatives

• Previous independent auditors (Macias Gini & O'Connell LLP and Marcum LLP) expressed "substantial doubt as to the Company's ability to continue as a going concern" in their audit reports for fiscal years ended May 31, 2022, May 31, 2023, and May 31, 2024.
• BF Borgers CPA PC, previously engaged as the independent auditor for fiscal year 2024, was dismissed following an SEC order on May 3, 2024, that permanently barred the firm and its principal from appearing or practicing before the SEC.
• The proposal to increase authorized common stock by 500,000,000 shares will result in dilution of existing stockholders' ownership, voting power, share value, and other interests.
• Broker non-votes and abstentions will have the effect of a vote against the proposal to increase authorized common stock.
• Robert Hoffman, the new Chief Financial Officer, had an initial report on Form 3 and a Form 4 reporting the award of stock options filed after their due dates, indicating a delinquent Section 16(a) report.

Risks

• There is substantial doubt about the Company's ability to continue as a going concern, as noted by previous independent auditors.
• Future issuances of additional common stock, if the authorization increase is approved, will dilute the ownership, voting power, share value, and other interests of existing stockholders.
• The issuance of authorized but unissued stock could potentially be used to deter a hostile takeover that might otherwise be beneficial to stockholders by diluting a potential suitor's shares or issuing shares to a friendly party.
• The Company's continued operations and pursuit of strategic goals are dependent on future financings to raise necessary capital.
• The successful implementation of strategic goals relies on the Company's continued ability to attract, retain, and motivate highly qualified management, clinical and scientific personnel, and advisors.

Future Outlook

The Company believes that increasing the number of authorized shares of common stock is essential for its continued operations and to meet future business and financial needs. These needs include raising capital through future financings to advance its lead product candidate, leronlimab, towards regulatory approval, pursuing other potential business expansion opportunities, satisfying existing payment obligations in shares rather than cash, and attracting, retaining, and motivating highly qualified personnel through equity awards. Management anticipates that such transactions, despite diluting existing stockholders, would ultimately increase the overall value of the Company.

Management Comments

• Jacob Lalezari, CEO: "We are excited about the future of our Company. It is vitally important that your shares are represented and voted, whether or not you are able to attend the virtual meeting."
• Board of Directors: "The Board believes that it is essential to the Company's continued operations to have additional authorized shares of common stock available for future issuance."
• Compensation Committee: "The Compensation Committee unanimously concluded that none of the performance goals had been met, but also determined that both executive officers had made exemplary efforts during fiscal year 2025 that improved the Company's prospects in future years."

Industry Context

The biotechnology industry, particularly for pre-commercial companies like CytoDyn, is highly capital-intensive, requiring substantial and continuous funding for research and development, clinical trials (such as for leronlimab), and regulatory processes. The Company's proposal to significantly increase authorized common stock for future financings and equity compensation is a common strategy in this sector to ensure operational continuity and attract talent. The reliance on equity-based incentives and the need for frequent capital raises are characteristic of companies in the development stage, where revenue generation is often years away.

Comparison to Industry Standards

• The Compensation Committee benchmarks executive and director compensation against a peer group of 17 pre-commercial, publicly traded biotechnology companies conducting Phase I/II trials for up to five drugs, utilizing an independent compensation consultant (Aon/Radford).
• The executive compensation program, comprising base salary, cash incentives, and long-term equity incentives (stock options), aligns with the predominant practices observed in pre-revenue biotechnology companies.
• The cancellation of existing stock options with higher exercise prices and the concurrent grant of new options with a lower exercise price ($0.21 per share) in January 2024 was a specific strategy to incentivize employee retention and performance, and to manage dilution, a practice that can be seen in companies seeking to re-motivate employees during periods of stock price decline.
• The repeated expression of "substantial doubt as to the Company's ability to continue as a going concern" by independent auditors (Macias Gini & O'Connell LLP and Marcum LLP) for three consecutive fiscal years (FY22, FY23, FY24) is a significant deviation from the financial health standards of a stable, publicly traded company in any industry, including biotechnology.
• The dismissal of BF Borgers CPA PC as an independent auditor due to an SEC order permanently barring the firm and its principal from practicing before the SEC is an unusual and severe event, indicating a failure to meet regulatory and professional standards for audit services, which is not comparable to standard industry practices.

Management Changes

Corporate Governance

Legal Proceedings

• The SEC issued an order on May 3, 2024, permanently barring BF Borgers CPA PC and its principal from appearing or practicing before the SEC. This regulatory action led to the Company's dismissal of BF Borgers as its independent auditor.

Related Party Transactions

• The Company has an outstanding balance of approximately $0.3 million owed to Lalezari Medical Corp., dba Quest Clinical Research (Quest), owned by current CEO Dr. Jacob Lalezari, as of August 31, 2025. This relates to past COVID-19 clinical trials conducted under a Clinical Trial Agreement (CTA) negotiated by a former CRO years before Dr. Lalezari's CEO appointment, with terms comparable to unrelated clinical locations.
• Since June 1, 2023, the Company has paid Quest approximately $0.1 million for its services.
• Since Dr. Lalezari became CEO in November 2023, the Company incurred approximately $11,428 for services performed at Quest, conducted by an independent contractor serving as the designated principal investigator.

Stakeholder Impact

• **Shareholders**: Face potential significant dilution from the proposed increase in authorized common stock, which is intended for future capital raises and equity compensation. They have the opportunity to influence corporate governance, executive compensation, and auditor selection through their votes. The persistent 'going concern' doubt and auditor issues present a material risk to their investment.
• **Employees, Officers, Directors, Consultants, and Advisors**: Stand to benefit from future equity awards, which are a key component of the Company's compensation strategy to attract, retain, and motivate highly qualified personnel. The cancellation and replacement of stock options in January 2024 aimed to further incentivize retention and performance.
• **Creditors**: The repeated 'going concern' qualification in audit reports could negatively impact the Company's creditworthiness and the terms under which it can secure future financing.
• **Patients/Public**: The Company's strategic goal of advancing leronlimab towards regulatory approval implies a potential future benefit for patients if the drug is successfully developed and commercialized.

Next Steps

• Stockholders are urged to vote on the proposals for the Annual Meeting by November 20, 2025, for electronic/telephonic votes, or by returning proxy cards.
• If the proposal to increase authorized shares is approved, the amendment to the Certificate of Incorporation will become effective upon filing with the Secretary of State of Delaware.
• The Company intends to utilize the additional authorized shares for future financings, equity awards, satisfying payment obligations in shares, and potential strategic transactions.
• The Audit Committee will reconsider the appointment of CBIZ CPAs P.C. if stockholders do not ratify it.
• The Board and Compensation Committee will consider the outcome of the advisory vote on executive compensation and the preferred frequency for future votes when making future decisions.

Key Dates

Recommendation

The filing reveals several critical issues that warrant a 'sell' recommendation for a seasoned investor. The most significant concern is the persistent 'substantial doubt as to the Company's ability to continue as a going concern' noted by multiple independent auditors for three consecutive fiscal years. This indicates severe financial distress and a high risk of business failure. Furthermore, the dismissal of an auditor due to an SEC order permanently barring the firm and its principal from practice raises serious questions about the Company's financial reporting integrity and oversight. The proposal to increase authorized common stock by 500 million shares, explicitly for future financings, signals an imminent and substantial dilution for existing shareholders, which will likely depress the stock price. While the Company is taking steps in corporate governance, these fundamental financial and operational challenges, coupled with the need for significant dilutive capital raises, present an extremely high-risk investment profile with a strong likelihood of further value erosion.

Keywords

CytoDyn, CYDY, SEC filing, proxy statement, annual meeting, shareholder vote, authorized shares, common stock, capital raise, dilution, corporate governance, executive compensation, director election, auditor ratification, going concern, biotechnology, leronlimab, clinical trials, risk management, cybersecurity